Recurrent Hepatitis C Post OLT for HCC and Cirrhosis

Slides:



Advertisements
Similar presentations
Bruix J, et al. Presented at the 44 th Annual Meeting of the European Association for the Study of the Liver (EASL), April 24, 2009, Copenhagen, Denmark.04/28/09.
Advertisements

Treatment-experienced HCV genotype 1 patients Bill Sievert Sally Bell.
Management of Chronic Hepatitis C in 2013
TWH LIVER CENTRE UHN centre of excellence A case study: Hepatitis C treatment and severe anemia Colina Yim RN(EC), MN Nurse Practitioner CAHN 2013.
Penny R. Thayer, FNP, BC Gastro/Hepatology NP James H. Quillen, VAMC.
Phase 3 Treatment Naïve and Treatment Experienced Renal Disease
National Hepatitis C Database Dr Lelia Thornton Health Protection Surveillance Centre December 2012.
NYU Medical Grand Rounds Clinical Vignette Jeffrey Mayne, MD Third Year Resident Internal Medicine 1/17/2012 U NITED S TATES D EPARTMENT OF V ETERANS A.
Guzman, Alexander Joseph Hipolito, April Lorraine
Differences between radiology and histopathology: Are we judging correctly? Simona Onali 1, Emmanuel Tsochatzis 1, James O’Beirne 1, Aileen Marshall 1,
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
+ Liver Transplantation for PSC Patients A Transplant Surgeon’s Perspective Tiffany Anthony, MD Annette C. and Harold C. Simmons Transplant Institute Baylor.
NYU Medical Grand Rounds Clinical Vignette Alexander Jow, PGY-3 February 21, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.
ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.
FT in prognostic of HBV FibroTest: predictive value in HBV.
Department of Medicine Grand Rounds Clinical Vignette Wednesday, March 4, 2009 Peter Shue, M.D.
BSG Pathology Section Liver Slide Seminar, Birmingham, March Clinical Summaries - Stefan Hübscher Prof. Stefan Hubscher Case 1 Male, age 52. Recent.
SOLAR-2 LDV/SOF + RBV Randomisation of the 7 groups 1 : 1 Open-label SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype.
SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.
SOF/VEL 400/100 mg qd N = 75 W24 SOF/VEL > 18 years Chronic HCV infection Genotype 1 to 6 Naïve or treatment-experienced No prior treatment with NS5A or.
Clinical Case HCV therapy following liver transplantation.
Open-label W24 ≥ 18 years Chronic HCV infection All genotypes HCV RNA ≥ 10,000 IU/ml Liver transplantation months earlier Child Pugh ≤ 7 and MELD.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
Setting the Scene. Non A, non B Hepatitis  Early 1970’s recognised that 2/3 of post transfusional hepatitis were –ve for both Hep A & Hep B Non Hep A.
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
경희대학교병원 간암 다학제증례집담회 Multidisciplinary case conference Liver Cancer Conference 소화기 센터 회의실
Benign Liver Masses in HIV Patient
Recurrent hepatitis with Halogenated Anesthetics
Dr. Mohammed Omar Khalifa
No HBV or HIV co-infection
Hepatocellular Carcinoma: Diagnosis and Management
National Hepatitis C Database
129 patients with chronic hepatitis C
Before the start of therapy
Design Randomisation 1 : 1 Open-label W16 W24 > 18 years
Phase 3 Treatment-Naïve and Treatment-Experienced
Proteinuria in a Renal transplant Recipient
Missing Cirrhosis on CT Scan
HCC Developing in Non-Cirrhotic with History of HBV
Liver Cancer Conference
HCV & liver transplantation
Clinical features of resected hepatocellular carcinoma emerging after sustained virological response against chronic hepatitis C Hepato-biliary-pancreatic.
HCC.
SOF/VEL + GS-9857 in genotypes 1-6 Phase II
Successful TACE for HCC
Chapter 12 Liver Transplantation 1
Fatal Liver Injury with a Food Supplement in Transplant Patient
Orthotopic liver transplant, recurrent non-alcoholic steatohepatitis
Successful TACE followed by OLT for HCC in Alcoholic Cirrhosis
Successful Tace in Patient with large HCC
AFP > 9000 without demonstrable HCC
Chapter 12 Liver Transplantation 1
History 56 y/o male from Cuba newly diagnosed with hepatitis C genotype 2b in Jan 2008 No symptoms of decompensation.
Alcoholic hepatitis with diffuse interstitial fibrosis
Cirrosi scompensata e trapianto di fegato: l’esperienza in real world
ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.
R Moreau, L Elkrief, C Bureau et al. Gastroenterology. Aug [Epub]
Liver cancer: Approaching a personalized care
Hepatitis C Virus Infection in the Older Patient
CT-SCAN & MRI LIRADS 2018 Dr. NGUYỄN HỒ TRÚC LINH - MRI.
Donor Allocation Policy in the US
Design W12 Open-label Liver transplant recipients
Presentation transcript:

Recurrent Hepatitis C Post OLT for HCC and Cirrhosis

History 76 year old white female with chronic hepatitis C (genotype 1b) acquired in 1975 through blood transfusion HCV cirrhosis H/O varices No encephalopathy No ascites

Hepatitis C Biopsy G-4 S-3 (June 1999) Interferon (standard) and RBV in 1999 – 2000 (6 months) Virological and biochemical remission Stopped after 6 months due to Profound anemia Erythema nodosum Pegylated interferon (40mcg) + RBV (800mg) in 2001. Stopped after 3 months due to severe anemia despite GF supplementation. Cirrhosis of liver documented on biopsy in 2002 (grade 4 and stage 4)

Clinical Course AFP high 25.5 in March 2003 but U/S negative Development of pedal edema (03) and ascites (April 04) – MELD of 9 (August 04) Secondary iron overload with ferritin of 1417, iron 235 MRI showed nodules (Siderotic?) HFE phenotype is negative Phlebotomy 250 cc/month EGD showed esophageal varices (grade 2–3), never bled, on nadolol

Clinical Course Decompensated cirrhosis with a MELD score of 10 AFP 14 (4/06) US in 4/06 showed 3 lesions in the right lobe measuring 1.2x1.2x1.3cm, 2.7x3.2x3.3 cm and 1.8x1.4X2 cm

Liver Transplantation Roux-en-Y liver transplant on 7/9/06 for decompensated cirrhosis and HCC (within Milan criteria) CMV +D/–R Explant pathology Well to moderately differentiated multifocal HCC Total 5 lesions, largest 2.5cm (necrotic)

Post Transplant Course Recurrent HCV infection on biopsy (grade 3 and stage 1 with mild ACR) Treated for rejection episode Malnutrition and anemia CMV positive by PCR and CMV positive on liver biopsy. Treated with gancyclovir Episode of rejection when CMV positive Most recently on Rapa and steroid

Follow-up AFP within 2–3 range since transplanted (6 years) No HCC recurrence Recurrent HCV not treated after the OLT due to severe adverse effects in the past

Follow-up triple phase CT at one year

Follow-up triple phase CT (one year) Follow-up triple phase CT at two years